 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12345678910111213...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 12, 2024
P1, N=29, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Dec 2024 | Trial primary completion date: Mar 2026 --> Dec 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: COLIBRI: COL Immunotherapy Before Radiochimio + Ipilimumab (clinicaltrials.gov) - Dec 12, 2024
P=N/A, N=40, Completed, Sponsor: ARCAGY/ GINECO GROUP
Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Dec 2024 | Trial primary completion date: Mar 2026 --> Dec 2024 Active, not recruiting --> Completed
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: FINN: A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 12, 2024
P=N/A, N=825, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: CheckMate 73L: A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (clinicaltrials.gov) - Dec 12, 2024
P3, N=925, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 11, 2024
P3, N=1147, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=831 --> 1147 | Trial primary completion date: Jun 2025 --> Aug 2024
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: CheckMate 9N9: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (clinicaltrials.gov) - Dec 11, 2024
P1/2, N=325, Completed, Sponsor: Bristol-Myers Squibb
N=831 --> 1147 | Trial primary completion date: Jun 2025 --> Aug 2024 Active, not recruiting --> Completed
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: BrUOG 324: Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma (clinicaltrials.gov) - Dec 11, 2024
P2, N=22, Active, not recruiting, Sponsor: Brown University
Active, not recruiting --> Completed Trial completion date: Jul 2024 --> Jan 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date: NeoRelapse: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (clinicaltrials.gov) - Dec 11, 2024
P2, N=25, Recruiting, Sponsor: University of Utah
Trial completion date: Jul 2024 --> Jan 2025 Initiation date: Nov 2024 --> Feb 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Dec 10, 2024
P1, N=30, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Nov 2024 --> Feb 2025 Suspended --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Checkpoint block: Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. (Pubmed Central) - Dec 10, 2024
P1
Suspended --> Recruiting Intraoperative iCer IPI?+?NIVO with postoperative iCav NIVO
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial termination: Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma (clinicaltrials.gov) - Dec 10, 2024
P1, N=6, Terminated, Sponsor: Mayo Clinic
Intraoperative iCer IPI?+?NIVO with postoperative iCav NIVO Trial completion date: Jul 2025 --> Apr 2024 | Active, not recruiting --> Terminated; Lack of funding
- | Trial completion date, Trial primary completion date: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (clinicaltrials.gov) - Dec 10, 2024
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2025 --> Apr 2024 | Active, not recruiting --> Terminated; Lack of funding Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- Yervoy (ipilimumab) / BMS
Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma () - Dec 7, 2024 - Abstract #ASH2024ASH_9278;
The lower dose of LEN used every other month in our trial makes it unlikely that the responses observed were due to LEN; rather, they likely were due to immunomodulation from immunotherapy with Ipi. In the era of CAR-T and targeted therapy, the combination of Ipi+LEN could be studied in patients who do not achieve complete response to those treatments.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Impact of Various Combinations of Potentially Immunogenic Therapeutics on the T Cell Response in Acute Myeloid Leukemia () - Dec 7, 2024 - Abstract #ASH2024ASH_7872;
The ELISpot results cannot be compared with the CFI results in all cases, but this was feasible for some results.Taken together, combinations of immunotherapeutic approaches increase antigen-specific immune responses against leukemic cells. Especially the combination of LAA peptides with the anti-PD-1 antibody and one further immunomodulating drug, like AZA, could be an interesting option for further studies.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Outcomes in Patients with Cancer-Associated Venous Thromboembolism Receiving Immune Checkpoint Inhibitors: A Matched Cohort Study () - Dec 7, 2024 - Abstract #ASH2024ASH_7649;
In our study, treatment with ICIs was not significantly associated with either recurrent VTE or bleeding. Future research is needed to elucidate the prognosis of cancer thrombosis patients receiving systemic therapy in effort to mitigate the risk of recurrent thrombosis and bleeding complications.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data. (Pubmed Central) - Dec 6, 2024
This study suggests NIVO+IPI may be a cost-effective first-line treatment when compared with chemo in a US setting given a threshold of US$150,000 per QALY. The cost-effectiveness analysis used a mixture-cure approach, which may offer a more appropriate modelling method in immuno-oncology given LTR, by more accurately capturing the potential treatment benefit.
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Adverse events, Real-world evidence, Real-world, Metastases: Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma. (Pubmed Central) - Dec 5, 2024
The cost-effectiveness analysis used a mixture-cure approach, which may offer a more appropriate modelling method in immuno-oncology given LTR, by more accurately capturing the potential treatment benefit. Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: KETOREIN: A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Dec 5, 2024
P=N/A, N=3, Terminated, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation. N=60 --> 3 | Trial completion date: Nov 2024 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2024 --> May 2024; Recruitment challenges: competition with another microbiome trial, patient refusal to join a dietary intervention study, poor tolerance of oral DPD (Grade 2 mucositis), and issues with organizing biological sample collection.
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: CheckMate 238: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (clinicaltrials.gov) - Dec 4, 2024
P3, N=906, Completed, Sponsor: Bristol-Myers Squibb
N=60 --> 3 | Trial completion date: Nov 2024 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2024 --> May 2024; Recruitment challenges: competition with another microbiome trial, patient refusal to join a dietary intervention study, poor tolerance of oral DPD (Grade 2 mucositis), and issues with organizing biological sample collection. Active, not recruiting --> Completed
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review. (Pubmed Central) - Dec 3, 2024
For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases...Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Real-world evidence, PD(L)-1 Biomarker, Real-world: Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. (Pubmed Central) - Dec 3, 2024
The highest-grade TRAE was 1 to 2 in 58% of these patients and 3 or higher in 42% Treatment discontinuation due to a TRAE occurred in 22% of patients. In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov) - Dec 2, 2024
P1/2, N=46, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar. Trial completion date: Oct 2025 --> Apr 2027 | Trial primary completion date: Oct 2024 --> Apr 2026
- ||| Opdivo (nivolumab) / BMS, Zejula (niraparib) / GSK, J&J, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: Parpvax: Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (clinicaltrials.gov) - Dec 2, 2024
P1/2, N=104, Completed, Sponsor: University of Pennsylvania
Trial completion date: Oct 2025 --> Apr 2027 | Trial primary completion date: Oct 2024 --> Apr 2026 Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Oct 2024
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Results of 10-year follow-up of the nivolumab plus ipilimumab combination in advanced melanoma from the phase 3 trial, CheckMate 067 (Poster area) - Nov 29, 2024 - Abstract #JDP2024JDP_955;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
A case of metastatic melanoma who developed Vogt-Koyanagi-Harada syndrome following treatment with ipilimumab and nivolumab (Poster area) - Nov 29, 2024 - Abstract #JDP2024JDP_776;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Large vessel vasculitis under ipilimumab/nivolumab dual immunotherapy (Poster area) - Nov 29, 2024 - Abstract #JDP2024JDP_667;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Effectiveness of treatment with ipilimumab/nivolumab or targeted therapy as salvage treatment after escape from nivolumab used as an adjuvant: descriptive study on 18 patients (Poster area) - Nov 29, 2024 - Abstract #JDP2024JDP_663;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Spectacular effectiveness of the ipilimumab-nivolumab combination in metastatic squamous cell carcinoma (Poster area) - Nov 29, 2024 - Abstract #JDP2024JDP_655;
- Encorafenib plus binimetinib followed by ipilimumab plus nivolumab versus ipilimumab plus nivolumab in patients with BRAF-V600E/K mutated advanced melanoma: results from the EORTC (EBIN) phase II study (Room 251) - Nov 29, 2024 - Abstract #JDP2024JDP_316;
- || Review, Journal: Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) - Nov 29, 2024
Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization. Also of interest are studies for patients with Child-Pugh B liver function and adding new checkpoint molecules to the current standard platforms.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Nov 29, 2024
P2, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4. (Pubmed Central) - Nov 28, 2024
Mechanistically, a 6.3-fold increase in PD1/CTLA-4 BsAb accumulation in tumors due to the tumor targeting ability of aPD1, and the PD1/CTLA-4 BsAb significantly reduces the adverse colitis event in healthy mice, compared to aPD1 and aCTLA-4. Thus, these findings provide a novel approach to enhance antitumor therapy using aPD1 and aCTLA-4.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting. (Pubmed Central) - Nov 28, 2024
Thus, these findings provide a novel approach to enhance antitumor therapy using aPD1 and aCTLA-4. Our results are consistent with those from the Checkmate 067 study, except for the objective response rate and the incidence of toxicities, which proved to be lower in our analysis.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma. (Pubmed Central) - Nov 27, 2024
ICOSLG expression was associated with CD64, a specific marker of M1 macrophages, at baseline in the patient samples who received cetirizine concomitantly with checkpoint inhibitors, but this association was not present in subjects who had not received cetirizine. In conclusion, our results show that the clinical advantage of concomitant treatment with cetirizine during checkpoint inhibition in patients with malignant melanoma is associated with high ICOSLG expression, which could predict the response to immune checkpoint inhibitor blockade.
- ||| Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial completion date, Tumor mutational burden: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma (clinicaltrials.gov) - Nov 27, 2024
P2, N=14, Active, not recruiting, Sponsor: Georgetown University
In conclusion, our results show that the clinical advantage of concomitant treatment with cetirizine during checkpoint inhibition in patients with malignant melanoma is associated with high ICOSLG expression, which could predict the response to immune checkpoint inhibitor blockade. Suspended --> Active, not recruiting | N=27 --> 14 | Trial completion date: May 2024 --> Dec 2024
- ||| ANV419 / Anaveon
Trial completion, Enrollment change, Trial completion date, Monotherapy, Metastases: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma (OMNIA-1). (clinicaltrials.gov) - Nov 27, 2024
P1/2, N=29, Completed, Sponsor: Anaveon AG
Suspended --> Active, not recruiting | N=27 --> 14 | Trial completion date: May 2024 --> Dec 2024 Recruiting --> Completed | N=130 --> 29 | Trial completion date: Dec 2024 --> Aug 2024
- | Opdivo (nivolumab) / BMS, Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer, Yervoy (ipilimumab) / BMS
Journal: Anti-Cancer Drug-Induced Lyell's Syndrome: A Series of Two Patients. (Pubmed Central) - Nov 26, 2024
(2) TEN in a man with metastatic melanoma treated with Nivolumab and Ipilimumab. Despite quick medical treatment and transfer to a severe burn unit, both patients died of TEN.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Adverse events, Checkpoint inhibition: Incidence of immune-related adverse events in U.S. veterans treated with immune checkpoint inhibitors. (Pubmed Central) - Nov 26, 2024
These findings are consistent with recent studies in clinical populations that demonstrate higher irAE incidence rates than originally reported in clinical trials. Our findings may enhance prompt recognition and treatment of irAEs for VA patients.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Monotherapy: CheckMate 74W: A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (clinicaltrials.gov) - Nov 26, 2024
P3, N=26, Completed, Sponsor: Bristol-Myers Squibb
Our findings may enhance prompt recognition and treatment of irAEs for VA patients. Terminated --> Completed
- || Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer, Yervoy (ipilimumab) / BMS
Clinical, P1 data, Journal, Metastases: Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial. (Pubmed Central) - Nov 25, 2024
P1
Terminated --> Completed With extended follow-up, RIN combination therapy demonstrated durable clinical benefit in a subset of patients with NLM MSS metastatic colorectal cancer, including potential cure in 3 responders who remain disease-free >
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical data, Retrospective data, Journal, Combination therapy, Checkpoint inhibition, Metastases: Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan. (Pubmed Central) - Nov 25, 2024
This study confirms clinical benefit of ICI combination therapy for metastatic nccRCC patients in real-world settings. Furthermore, the effectiveness of combination therapy was comparable between patients aged?<?75 and those ?75
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, Retrospective data, Review, Journal, Checkpoint inhibition: Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 (Pubmed Central) - Nov 25, 2024
Furthermore, the effectiveness of combination therapy was comparable between patients aged?<?75 and those ?75 Among PD-L1 TPS 1-49
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, Journal, Patient reported outcomes, Metastases: Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study. (Pubmed Central) - Nov 25, 2024
PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. This knowledge may accelerate development of prognostic tools to manage treatment in patients with previously untreated unresectable or metastatic melanoma who undergo immunotherapy.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P2 data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma). (Pubmed Central) - Nov 25, 2024
P2
Expanded prospective studies are warranted. ClinicalTrials.gov registry: NCT02834013.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: NeoRad: BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab (clinicaltrials.gov) - Nov 25, 2024
P2, N=25, Recruiting, Sponsor: Brown University
ClinicalTrials.gov registry: NCT02834013. Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: SCANDIUM-III: PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases (clinicaltrials.gov) - Nov 25, 2024
P3, N=40, Recruiting, Sponsor: Vastra Gotaland Region
Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Feb 2025 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov) - Nov 24, 2024
P2, N=46, Active, not recruiting, Sponsor: Brown University
Not yet recruiting --> Recruiting Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Real-world evidence, Real-world: Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM). (Pubmed Central) - Nov 24, 2024
Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025 This multicenter RWD study demonstrated the clinically meaningful benefit of first-line ipilimumab and nivolumab in LATAM patients with unresectable or metastatic PM, and data is consistent with previous trial findings.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas. (Pubmed Central) - Nov 22, 2024
P1
We show nivolumab plus ipilimumab can be safely administered prior to standard radiotherapy for newly diagnosed gliomas and is operationally feasible. Clinicaltrials.gov NCT03425292 registered February 7, 2018.
- ||| BMS-986408 / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 22, 2024
P1/2, N=101, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Clinicaltrials.gov NCT03425292 registered February 7, 2018. N=402 --> 101 | Trial primary completion date: Oct 2025 --> Aug 2024